» Articles » PMID: 24758240

Guidelines for the Diagnosis and Treatment of Helicobacter Pylori Infection in Korea, 2013 Revised Edition

Overview
Specialty Gastroenterology
Date 2014 Apr 25
PMID 24758240
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

The Korean College of Helicobacter and Upper Gastrointestinal Research first developed guidelines for the diagnosis and treatment of Helicobacter pylori (H. pylori) infection in 1998, and revised guidelines were proposed in 2009 by the same group. Although the revised guidelines were based on a comprehensive review of published articles and the consensus of expert opinions, the revised guidelines were not developed using an evidence-based process. The new guidelines presented in this study include specific changes regarding indication and treatment of H. pylori infection in Korea, and were developed through the adaptation process using an evidence-based approach. After systematic review of the literature, six guidelines were selected using the Appraisal of Guidelines for Research and Evaluation (AGREE) II process. A total of 21 statements were proposed with the grading system and revised using the modified Delphi method. After the guideline revisions, 11 statements about indication of test and treatment, four statements about diagnosis, and four statements about treatment of H. pylori infection were developed. The revised guidelines were reviewed by external experts before receiving official endorsement from the Korean College of Helicobacter and Upper Gastrointestinal Research, and disseminated to physicians and other medical professionals for use in clinical practice in Korea. The guidelines will continue to be updated and revised periodically.

Citing Articles

Comparison of GastroPanel and GENEDIA in Diagnosing Infection and Gastric Lesions.

Choi Y, Kim N, Lim S, Park J, Lee J, Kim Y J Cancer Prev. 2025; 29(4):148-156.

PMID: 39790230 PMC: 11706727. DOI: 10.15430/JCP.24.024.


The C/C Genotype of rs1231760 in Is a Risk Factor for the Progression of -Positive Atrophic Gastritis by Increasing Expression.

Yamaguchi N, Sakaguchi T, Wei J, Tazoe Y, Inamine T, Fukuda D Diagnostics (Basel). 2024; 14(22).

PMID: 39594230 PMC: 11592620. DOI: 10.3390/diagnostics14222563.


Development and validation of next-generation sequencing panel for personalized eradication treatment targeting multiple species.

Min B, Seo M, Bae J, Kim J, Kim J Front Cell Infect Microbiol. 2024; 14:1379790.

PMID: 39268485 PMC: 11390507. DOI: 10.3389/fcimb.2024.1379790.


Risk of Ischemic Stroke in Relation to Infection and Eradication Status: A Large-Scale Prospective Observational Cohort Study.

Jeon E, Kim N, Kim B, Hwang I, Kim S, Kim J Gut Liver. 2024; 18(4):642-653.

PMID: 38712396 PMC: 11249949. DOI: 10.5009/gnl230458.


Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens.

Lim C, Oh J Gut Liver. 2024; 18(6):970-976.

PMID: 38712395 PMC: 11564998. DOI: 10.5009/gnl230453.